tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2024 Nov;30(11):2352-2361.
doi: 10.3201/eid3011.240043.
Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022
Anna Bratcher, Szu-Yu Kao, Kelly Chun, Christos J Petropoulos, Adi V Gundlapalli, Jefferson Jones, Kristie E N Clarke
We studied SARS-CoV-2 binding and neutralizing antibody titers among previously infected persons in the United States over time. We assayed SARS-CoV-2 spike protein receptor-binding domain and neutralizing antibody titers for a convenience sample of residual clinical serum specimens that had evidence of prior SARS-CoV-2 infection gathered during January 2021-February 2022. We correlated titers and examined them by age group (<18, 18-49, 50-64, and >65 years) across 4 different SARS-CoV-2 variant epochs. Among selected specimens, 30,967 had binding antibody titers and 744 had neutralizing titers available. Titers in specimens from children and adults correlated. In addition, mean binding antibody titers increased over time for all age groups, and mean neutralization titers increased over time for persons 16-49 and >65 years of age. Incorporating binding and neutralization antibody titers into infectious disease surveillance could provide a clearer picture of overall immunity and help target vaccination campaigns.
Keywords: COVID-19; SARS; SARS-CoV-2; United States; binding antibodies; coronavirus; coronavirus disease; neutralizing antibodies; respiratory infections; serosurveillance; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
. 2024 Nov;30(11):2352-2361.
doi: 10.3201/eid3011.240043.
Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022
Anna Bratcher, Szu-Yu Kao, Kelly Chun, Christos J Petropoulos, Adi V Gundlapalli, Jefferson Jones, Kristie E N Clarke
- PMID: 39447163
- DOI: 10.3201/eid3011.240043
We studied SARS-CoV-2 binding and neutralizing antibody titers among previously infected persons in the United States over time. We assayed SARS-CoV-2 spike protein receptor-binding domain and neutralizing antibody titers for a convenience sample of residual clinical serum specimens that had evidence of prior SARS-CoV-2 infection gathered during January 2021-February 2022. We correlated titers and examined them by age group (<18, 18-49, 50-64, and >65 years) across 4 different SARS-CoV-2 variant epochs. Among selected specimens, 30,967 had binding antibody titers and 744 had neutralizing titers available. Titers in specimens from children and adults correlated. In addition, mean binding antibody titers increased over time for all age groups, and mean neutralization titers increased over time for persons 16-49 and >65 years of age. Incorporating binding and neutralization antibody titers into infectious disease surveillance could provide a clearer picture of overall immunity and help target vaccination campaigns.
Keywords: COVID-19; SARS; SARS-CoV-2; United States; binding antibodies; coronavirus; coronavirus disease; neutralizing antibodies; respiratory infections; serosurveillance; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.